Obstacles in rare disease research and orphan drug development continue to include low patient numbers, difficult recruitment, and insufficient scientific and medical knowledge such as lack of natural history data and known, relevant endpoints. Until now, collection of such information has resided primarily with clinical experts and drug development companies. But the recognition of patient registries as key determinants in accelerating research and drug development progress has propelled significant interest from patient organizations over the last decade. Today, read more >